This requirement is due to the potential risks of exacerbating autoimmunity. However, patients with vitiligo or clinically stable autoimmune endocrine disease who are on appropriate replacement therapy (if such therapy is indicated) are eligible . 2.1.3.6 Concurrent use of systemic steroids, except for physiologic doses of systemic steroid replacement or local (topical , nasal, or inhaled) steroid use. Limited pharmacologic doses of systemic steroids (e.g., in patients with exacerbations of reactive airway disease or to prevent I.V. contrast allergic reaction or anaphylaxis in patients who have known contrast allergies) are allowed. 2.1.3.7 Patients who are receiving any other investigational agents within 28 days before start of study treatment. 2.1.3.8 Patients with untreated central nervous system metastases or local treatment of brain metastases within the last 6 months . Patients with stable brain metastasis for 6 months post- intervention are eligible. Subjects with chordoma will be eligible regardless of site of disease if other eligibility criteria are met. 2.1.3.9 History of allergic reactions attributed to compounds of similar chemical or biologic composition to MVA-brachyury -TRICOM or other agents used in study. 2.1.3.10 Serious or uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that, in the opinion of the investigator, would limit compliance with study requirements. 30 Abbreviated Title: Phase I MVA -Brachyury -TRICOM Version Date: September 14, 2016 Confidential 2.1.3.11 Pregnant women are excluded from this study due to the unknow n effects of the MVA - brachyury -TRICOM vaccine on the f etus or infant. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with MVA-brachyury- TRICOM , breastfeeding should be discontinued if the mother is treated with MVA -brachyury -TRICOM . These potential risks may also apply to other agents used in this study.